Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
Royal Marsden Hospital
Londres, Reino UnidoPublications en collaboration avec des chercheurs de Royal Marsden Hospital (14)
2023
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60
2021
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946
-
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
ESMO Open, Vol. 6, Núm. 2
2017
-
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
European Journal of Haematology, Vol. 99, Núm. 3, pp. 199-206
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
2016
-
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
Gynecologic Oncology, Vol. 142, Núm. 1, pp. 62-69
-
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): A randomised, double-blind, placebo-controlled phase 3 trial
The Lancet, Vol. 387, Núm. 10023, pp. 1066-1074
-
European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery
International Journal of Gynecological Cancer, Vol. 26, Núm. 7, pp. 1354-1363
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma
Blood, Vol. 128, Núm. 4, pp. 497-503
2014
-
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600
-
Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)
European Journal of Cancer
2013
-
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer
European Journal of Cancer, Vol. 49, Núm. 18, pp. 3831-3838